SLSung-Gyu Lee

Sung-Gyu Lee

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sung-Gyu Lee has a total of 664 co-authors. Here are the top co-authors by number of shared publications:

  • Gi-Won Song

    Division of Liver Transplantation and Hepatobiliary Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

    87 shared publications
  • Shin Hwang

    Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

    82 shared publications
  • Dong-Hwan Jung

    Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

    76 shared publications
  • Deok-Bog Moon

    Division of Liver Transplantation and Hepatobiliary Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

    73 shared publications
  • Chul-Soo Ahn

    Division of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

    66 shared publications
  • Gil-Chun Park

    Division of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

    66 shared publications

Latest Publications

  • Bilateral duct-to-duct anastomosis in dual left graft living donor liver transplantation: Bile duct position assessment after graft procurement and perfusion—A retrospective cohort study

    by Woo-Hyoung Kang, Deok-Bog Moon, Chul-Soo Ahn, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Gil-Chun Park, Shin Hwang, Ki-Hun Kim, Young-In Yoon, et al.

    In adult dual left liver graft living donor liver transplantation (LDLT), composite rotation of the right-sided graft alters the bile duct–portal vein relationship, making bilateral duct-to-duct (D-D) reconstruction technically challenging. Although bilateral D-D preserves endoscopic access and avoids enteric reconstruction, no structured intraoperative strategy has been established. From 36 consecutive dual left graft LDLT procedures, we propose a practical approach based on bile duct–portal vein positional patterns and a 2-stage intraoperative assessment. Bilateral D-D was achieved in 26 patients (72.2%) without bile leak. Biliary stricture occurred in 38.5% and was managed endoscopically in 88.9% without surgical reintervention. Portal vein narrowing developed in 8 patients (22.2%), most often when the right graft bile duct lay deeply posterior to the portal vein after rotation (55.6% vs. 11.1%–12.5% in other patterns). Among patients with narrowing and long-term follow-up, all 4 conservatively managed grafts developed right graft atrophy, whereas none of the 3 managed with intraoperative portal vein stenting did; no mortality was attributable to narrowing. Bilateral D-D is therefore achievable when guided by intraoperative assessment of the bile duct–portal vein relationship after composite rotation: hepaticojejunostomy should be performed without hesitation in unfavorable configurations, and intraoperative portal vein stenting should be considered selectively when narrowing is detected. In carefully selected patients, bilateral D-D is a feasible strategy that preserves endoscopic access; these single-center observations are exploratory and warrant prospective validation.

  • Open Access

    Outcomes of liver transplantation in critically ill patients admitted to an intensive care unit: a retrospective study

    by Dae-Hyeon Won, Young-In Yoon, Sung-Min Kim, Shin Hwang, Chul-Soo Ahn, Ki-Hun Kim, Deok-Bog Moon, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, et al.

    Dae-Hyeon Won, Young-In Yoon, Sung-Min Kim, Shin Hwang, Chul-Soo Ahn, Ki-Hun Kim, Deok-Bog Moon, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Gil-Chun Park, Woo-Hyoung Kang, Sung-Gyu Lee. Clin Transplant Res -0001;0:. https://doi.org/10.4285/ctr.26.0010

  • Open Access

    Eligibility and causes of disqualification among living liver donor candidates: A single-center analysis of 991 candidates

    by Eun-Ju Nam, Jong-Hyun Kim, Hae-In Shin, Young-In Yoon, Deok-Bog Moon, Ki-Hun Kim, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Gil-Chun Park, et al.

    Eun-Ju Nam, Jong-Hyun Kim, Hae-In Shin, Young-In Yoon, Deok-Bog Moon, Ki-Hun Kim, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Gil-Chun Park, Shin Hwang, Sung-Gyu Lee. Ann Liver Transplant -0001;0:. https://doi.org/10.52604/alt.25.0025

  • Open Access

    Therapeutic Targeting of miR-21 Restores SASH1 and Sensitizes HBV-HCC to Sorafenib

    by Kyuyoung Han, Eun-Kyoung Jwa, Suhyeon Ha, Jiye Kim, Ryunjin Lee, Eunkyeong Lee, Seoon Kang, Hye Ok Kim, Hyunhee Kwon, Dong-Hwan Jung, et al.

    Background: Sorafenib resistance remains a major barrier to effective therapy in hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC). Introduction: Here, we identified a previously undefined mechanism by which miR-21 promotes sorafenib resistance by suppressing the tumor suppressor SASH1 and enhancing HBx-driven PI3K/AKT/mTOR signaling. Methods: miR-21 expression was markedly elevated in HBV-HCC tissues, HBV-integrated HCC cell lines, and hypoxic conditions. Bioinformatic analyses and luciferase reporter assays confirmed SASH1 as a direct miR-21 target. Results: Mechanistically, SASH1 was functionally associated with HBx-related oncogenic signaling and influenced apoptotic responses. miR-21 inhibition reduced HBV-HCC cell proliferation, increased apoptosis, and restored sorafenib sensitivity in vitro. In an orthotopic HBV-HCC mouse model, the combined administration of miR-21 inhibitor and sorafenib elicited markedly greater tumor suppression and restoration of the SASH1 expression than either monotherapy did. Discussion: Therefore, these findings suggested that the miR-21/SASH1 pathway contributed to therapeutic resistance in HBV-associated HCC and highlighted that miR-21 targeting could be an efficient strategy to improve sorafenib response. Conclusions: The miR-21/SASH1 axis play a critical role in sorafenib resistance in HBV-associated HCC, and targeting miR-21 may provide a promising therapeutic strategy to enhance treatment efficacy.


  • Open Access

    AFP-PIVKA-II score as a simplified quantifiable surrogate biomarker for hepatocellular carcinoma recurrence following living donor liver transplantation

    by Dae Hyeon Won, Shin Hwang, Chul-Soo Ahn, Deok-Bog Moon, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Gil-Chun Park, Woo-Hyoung Kang, Young-In Yoon, et al.

    Dae Hyeon Won, Shin Hwang, Chul-Soo Ahn, Deok-Bog Moon, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Gil-Chun Park, Woo-Hyoung Kang, Young-In Yoon, Sung-Gyu Lee. Ann Liver Transplant -0001;0:. https://doi.org/10.52604/alt.25.0024

  • Open Access

    Survival and Recurrence in Liver Transplant Patients With Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma

    by I-Ji Jeong, Shin Hwang, Chul-Soo Ahn, Deok-Bog Moon, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Gil-Chun Park, Woo-Hyoung Kang, Young-In Yoon, et al.

    BACKGROUND Intrahepatic cholangiocarcinoma (ICC) can be an incidental finding in liver explants following liver transplantation (LT). This study aimed to evaluate the long-term post-transplant outcomes of patients with ICC. MATERIAL AND METHODS From 2003 to 2022, 25 patients with ICC were identified among 6,611 adult LT recipients through institutional database search. RESULTS The incidence of ICC among adult LT recipients was 0.4%. All cases were incidental findings in explanted livers. The mean ICC tumor size was 2.7±1.6 cm, and 22 patients had single ICC lesion. Concurrent second liver malignancies were found in 10 patients (40%): hepatocellular carcinoma (HCC) in 9 and combined HCC-cholangiocarcinoma in one. The 5-year all-type tumor recurrence (TR) and overall survival (OS) rates were 72.0% and 47.0%, respectively. The presence of second primary cancer had no significant impact on TR (P=0.832) or OS (P=0.533). Similarly, ICC tumor stage did not significantly affect TR (P=0.394) or OS (P=0.395). Among 15 patients with ICC alone, 11 (73.3%) experienced ICC recurrence. Of the 10 patients with concurrent malignancies, 7 (70.0%) experienced all-type TR: 5 with HCC and 2 with ICC. Notably, the 5-year ICC recurrence and OS rates in 5 patients with very early-stage ICC and no HCC recurrence were 20.0% and 80.0%, respectively. CONCLUSIONS ICC is a rare incidental finding in LT recipients, often coexisting with concurrent second liver malignancy. Overall prognosis following LT for ICC remains poor, except for those with very early-stage disease. Because all incidences of TR occurred within 5 years after transplant, rigorous surveillance is essential during this period.

  • Open Access

    Long-Term Patency of Hemashield Vascular Grafts Used for Middle Hepatic Vein Reconstruction During Living-Donor Liver Transplantation: A Single-Center Korean Experience

    by Dae Hyeon Won, Shin Hwang, Chul-Soo Ahn, Deok-Bog Moon, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Gil-Chun Park, Woo-Hyoung Kang, Young-In Yoon, et al.

    BACKGROUND The availability of homologous vein allografts is limited. Therefore, prosthetic vascular grafts can be used as alternatives for middle hepatic vein (MHV) reconstruction during living-donor liver transplantation (LDLT). This study evaluated the short- and long-term patency of MHV reconstructions using Hemashield vascular grafts and assessed their effect on post-transplant survival. MATERIAL AND METHODS This retrospective observational study included 149 adult LDLT recipients who underwent MHV reconstruction using Hemashield grafts at a single institution. Graft patency and survival outcomes were assessed over long-term follow-up. RESULTS The mean recipient age was 56.2±7.7 years, and the mean graft-to-recipient weight ratio was 1.06±0.25. V5 reconstruction was achieved through single, double, and triple anastomoses in 111, 32, and 2 patients, respectively. V8 reconstruction in 116, 20, and one patient was achieved through single, double, and triple anastomoses, respectively. In 100 and 49 cases, we used Hemashield grafts with diameters of 10 mm and 12 mm, respectively. Three patients (2.0%) developed early thrombosis that necessitated stent placement. The cumulative conduit occlusion-free survival rates were 81.0% at 3 months, 57.9% at 1 year, 48.7% at 3 years, and 43.8% at 5 years. Overall patient survival rates were 95.3% at 1 year, 89.1% at 3 years, and 85.7% at 5 years. No cases of graft migration or conduit-related infection were identified. CONCLUSIONS MHV reconstruction using Hemashield grafts demonstrated acceptable short- and long-term patency, with no migration or infection. These findings support the use of Hemashield grafts as a reliable and effective prosthetic option for MHV reconstruction during LDLT.

  • Open Access

    Prognostic validation of ADV and MoRAL scores for hepatocellular carcinoma recurrence following living donor liver transplantation: a long-term follow-up study

    by Young-In Yoon, Shin Hwang, Chul-Soo Ahn, Deok-Bog Moon, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Gil-Chun Park, Woo-Hyoung Kang, Sung-Gyu Lee

    Young-In Yoon, Shin Hwang, Chul-Soo Ahn, Deok-Bog Moon, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Gil-Chun Park, Woo-Hyoung Kang, Sung-Gyu Lee. Clin Transplant Res -0001;0:. https://doi.org/10.4285/ctr.25.0063


  • Open Access

    Long-Term Prognostic Significance of TACE-Induced Complete Pathological Response in Patients with Hepatocellular Carcinoma Who Have Undergone Liver Transplantation

    by I-Ji Jeong, Shin Hwang, Chul-Soo Ahn, Deok-Bog Moon, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Gil-Chun Park, Woo-Hyoung Kang, Young-In Yoon, et al.

    BACKGROUND Complete pathological response (CPR) after transcatheter arterial chemoembolization (TACE) is associated with improved posttransplant outcomes in patients with hepatocellular carcinoma (HCC). This study evaluated the prognostic significance of TACE-induced CPR in patients with HCC who underwent liver transplantation (LT). MATERIAL AND METHODS The records of 2238 patients who underwent primary LT for HCC between January 2006 and December 2020 were retrospectively reviewed; of these, 253 achieved explant pathology-confirmed TACE-induced CPR. Their clinical outcomes were analyzed. RESULTS These 253 patients underwent an average of 2.2±2.3 TACE sessions. The median number of non-viable tumors was 1, and the median maximal tumor size was 1.6 cm. At 1, 3, 5, 10, and 15 years, cumulative post-LT recurrence rates were 1.2%, 3.3%, 3.3%, 5.6%, and 5.6%, respectively; overall patient survival rates were 96.0%, 93.7%, 92.4%, 91.3%, and 82.1%, respectively. Larger tumors (>2 cm) and multiple non-viable tumors were independently associated with higher recurrence and reduced survival rates (P≤0.036). Cluster analysis identified patients with multiple non-viable tumors larger than 2 cm as a high-risk group; others comprised a low-risk group. Recurrence (P<0.001) and survival (P=0.018) rates were significantly lower in the high-risk group than in the low-risk group. CONCLUSIONS TACE-induced CPR is a strong prognostic indicator of favorable long-term outcomes after LT in patients with HCC. Stratification based on non-viable tumor size and number can identify high-risk patients with CPR who require closer surveillance. Less intensive follow-up may be sufficient for low-risk patients.

  • Open Access

    Donor-to-recipient sex match status has no prognostic effect on long-term survival following liver transplantation: a retrospective observational study

    by Woo-Hyoung Kang, I-Ji Jeong, Shin Hwang, Chul-Soo Ahn, Deok-Bog Moon, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Gil-Chun Park, Young-In Yoon, et al.

    Woo-Hyoung Kang, I-Ji Jeong, Shin Hwang, Chul-Soo Ahn, Deok-Bog Moon, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Gil-Chun Park, Young-In Yoon, Sung-Gyu Lee. Clin Transplant Res -0001;0:. https://doi.org/10.4285/ctr.25.0049